{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:13:09Z","timestamp":1771330389218,"version":"3.50.1"},"reference-count":19,"publisher":"Japan Epidemiological Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Epidemiology"],"published-print":{"date-parts":[[2006]]},"DOI":"10.2188\/jea.16.101","type":"journal-article","created":{"date-parts":[[2006,5,19]],"date-time":"2006-05-19T05:50:25Z","timestamp":1148017825000},"page":"101-106","source":"Crossref","is-referenced-by-count":9,"title":["Difference of Progression to AIDS According to CD4 Cell Count, Plasma HIV RNA Level and the Use of Antiretroviral Therapy among HIV Patients Infected through Blood Products in Japan"],"prefix":"10.2188","volume":"16","author":[{"given":"Miyuki","family":"Kawado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"991","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Weinstock H, Dale M, Linley L, Gwinn M. Unrecognized HIV infection among patients attending sexually transmitted disease clinics. Am J Public Health 2002; 92: 280-3.","DOI":"10.2105\/AJPH.92.2.280"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371101"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002; 155: 760-70.","DOI":"10.1093\/aje\/155.8.760"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17: 2227-36.","DOI":"10.1097\/00002030-200310170-00011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158: 687-94.","DOI":"10.1093\/aje\/kwg206"},{"issue":"6950","key":"6","first-page":"309","volume":"309","year":"1994","ISSN":"https:\/\/id.crossref.org\/issn\/0959-8146","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.","DOI":"10.1126\/science.272.5265.1167"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Begtrup K, Melbye M, Biggar RJ, Goedert JJ, Knudsen K, Andersen PK. Progression to acquired immunodeficiency syndrome is influenced by CD4 T-lymphocyte count and time since seroconversion. Am J Epidemiol 1997; 145: 629-35.","DOI":"10.1093\/oxfordjournals.aje.a009160"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigations. JAMA 1998; 280: 1497-503.","DOI":"10.1001\/jama.280.17.1497"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.20.2568"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-9.","DOI":"10.1016\/S0140-6736(03)13802-0"},{"key":"12","unstructured":"12. Hashimoto S, Yamaguchi T, Oka S, Yoshizaki K, Kimura S, Fukutake K, et al. CD4 cell counts, plasma HIV-RNA levels and use of antiretroviral therapy among patients with HIV infection through blood products. J AIDS Res 2001; 3: 16-22.(in Japanese)"},{"key":"13","unstructured":"13. Yamaguchi T, Hashimoto S, Oka S, Yoshizaki K, Kimura S, Fukutake K, et al. Trends in CD4 cell counts, plasma HIV-RNA levels and the use of antiretroviral therapy, and those relationships among patients with HIV infection through blood products. J AIDS Res 2001; 3: 23-30. (in Japanese)"},{"issue":"5","key":"14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2188\/jea.12.383","volume":"12","author":"YAMAGUCHI T","year":"2002","ISSN":"https:\/\/id.crossref.org\/issn\/0917-5040","issn-type":"print"},{"key":"15","unstructured":"15. Guideline of an infectious disease report -a standard of an infectious disease diagnosis -. Association of Japan public sanitation Foundation, 2005 (in Japanese)."},{"key":"16","unstructured":"16. SAS Institute Inc. SAS\/STAT User's Guide, version 8. SAS Institute Inc. Cary, NC, 1999."},{"key":"17","unstructured":"17. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51(RR-7): 1-55."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001; 15: 983-90.","DOI":"10.1097\/00002030-200105250-00006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ahdieh-Grant L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick JB, et al. When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epidemiol 2003; 157: 738-46.","DOI":"10.1093\/aje\/kwg036"}],"container-title":["Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jea\/16\/3\/16_3_101\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:51:04Z","timestamp":1656553864000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jea\/16\/3\/16_3_101\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.2188\/jea.16.101","relation":{},"ISSN":["0917-5040","1349-9092"],"issn-type":[{"value":"0917-5040","type":"print"},{"value":"1349-9092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}